electroCore Begins PTSD Study with First Patient Enrollments

Event summary

  • electroCore has enrolled the first eight patients in a PTSD study using its gammaCore™ nVNS device.
  • The investigator-led study, conducted with Acacia Clinics and the Vagus Nerve Society, aims to enroll up to 40 participants.
  • Primary endpoints include safety and changes in Clinician-Administered PTSD Scale (CAPS-5) scores over a 12-week treatment period.
  • The study is expected to run for approximately 10 months, with electroCore providing devices and an educational grant.

The big picture

electroCore’s PTSD study reflects the broader push toward non-invasive neuromodulation for mental health conditions, where traditional therapies often fall short. The company’s focus on bioelectronic medicine positions it in a niche with high unmet need, though success will depend on clinical validation and regulatory support. The study’s outcomes could influence investor sentiment and strategic partnerships in the neuromodulation sector.

What we're watching

Clinical Validation
Whether gammaCore nVNS can demonstrate efficacy in PTSD, expanding its potential market beyond chronic pain.
Regulatory Pathway
The pace at which positive results could lead to expanded FDA approvals for neuropsychiatric applications.
Competitive Positioning
How electroCore’s bioelectronic approach differentiates it in the growing neuromodulation space.

Related topics

Medical Devices